NASDAQ:SRZN Surrozen Q2 2024 Earnings Report $26.21 +0.05 (+0.19%) Closing price 04:00 PM EasternExtended Trading$26.22 +0.01 (+0.04%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Surrozen EPS ResultsActual EPS-$1.54Consensus EPS -$2.79Beat/MissBeat by +$1.25One Year Ago EPSN/ASurrozen Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASurrozen Announcement DetailsQuarterQ2 2024Date8/12/2024TimeAfter Market ClosesConference Call DateMonday, August 12, 2024Conference Call Time7:00AM ETUpcoming EarningsSurrozen's Q2 2026 earnings is estimated for Friday, August 14, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 7, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Surrozen Earnings HeadlinesHead-To-Head Contrast: Relay Therapeutics (NASDAQ:RLAY) vs. Surrozen (NASDAQ:SRZN)May 21, 2026 | americanbankingnews.comWe're Not Very Worried About Surrozen's (NASDAQ:SRZN) Cash Burn RateMay 17, 2026 | finance.yahoo.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.May 29 at 1:00 AM | InvestorPlace (Ad)Surrozen (SRZN) price target increased by 10.11% to 43.52May 14, 2026 | msn.comSurrozen Shareholders Support Board, Auditor and Pay PoliciesMay 14, 2026 | tipranks.comSurrozen to Present at Upcoming Healthcare Investor ConferenceMay 12, 2026 | globenewswire.comSee More Surrozen Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Surrozen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Surrozen and other key companies, straight to your email. Email Address About SurrozenSurrozen (NASDAQ:SRZN) is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity. The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis. Surrozen’s pipeline spans both preclinical and clinical stages and includes programs addressing ocular surface disease, gastrointestinal disorders and solid tumors—indications characterized by impaired tissue healing or dysregulated Wnt activity. To advance its pipeline, Surrozen has entered into strategic collaborations and research agreements with academic institutions and biopharmaceutical partners. These alliances are aimed at validating novel Wnt targets, enhancing antibody design and accelerating the translation of lead candidates into clinical development. The company is actively preparing multiple investigational new drug applications and expects to initiate additional clinical trials in the near term. Surrozen is led by President and Chief Executive Officer Laura Shawver, PhD, supported by a management team with deep expertise in antibody engineering, developmental biology and translational medicine. The company’s research and development operations are based in the San Francisco Bay Area, where it maintains dedicated laboratory and manufacturing facilities to support its growing pipeline.View Surrozen ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Shares Fall, Targets Rise—Markets and Analysts Diverge on SynopsysDollar Tree Keeps Winning After Family Dollar DivorceSalesforce Stock Finds Support as AI Momentum BuildsMarvell’s Pullback May Be the Setup Bulls Were Waiting ForSnowflake and the Snowballing Impact of its AI FlywheelPalomar’s High-Risk Insurance Strategy Is Paying Off BigThis Quantum Computing Stock May Be Closer to a Breakout Than You Think Upcoming Earnings Hewlett Packard Enterprise (6/1/2026)Palo Alto Networks (6/2/2026)Broadcom (6/3/2026)CrowdStrike (6/3/2026)Medtronic (6/3/2026)Ciena (6/4/2026)Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
